title: [Mechanisms, clinical profile and role of prostaglandin and                     prostamide analogues in antiglaucomatous therapy].
abstract: Prostaglandin and prostamide analogues belong to a new substance group which                         came into the market in the 1990s. They have revolutionised antiglaucomatous                         therapy by their once-daily dosing regimen and fewer side effects. Today,                         prostaglandin and prostamide analogues are approved as first-line therapy                         for patients with primary open-angle glaucoma and ocular hypertension. They                         lower the intraocular pressure primarily by increasing the uveoscleral                         outflow. Recent investigations have shown that they also improve the                         trabecular outflow facility and thus the conventional outflow pathways.                         Prostaglandin and prostamide analogues are highly efficient in lowering the                         intraocular pressure, for which they are superior to other antiglaucomatous                         substance groups. In particular, they appear to have a good control of                         24-hour intraocular pressure fluctuations by primarily improving the outflow                         pathways. Furthermore, they have less systemic side effects than β-blockers.                         However, their use is often associated with higher costs. In case of                         undesirable events, they mostly present with ocular symptoms. Based on their                         good clinical profile, prostaglandin and prostamide analogues play an                         important role in the primary and additive therapy for glaucoma.
authors: Augenklinik, Ludwig-Maximilians-Universität, Mathildenstrasse 8, Munich. alice.yu@med.uni-muenchen.de
authors: A
authors: A
authors: Yu
authors: U
authors: U
authors: Welge-Lüßen
mesh_terms: D000959:Antihypertensive Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D015232:Dinoprostone / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use*; D016527:Drug Costs / Q000706:statistics & numerical data; D004359:Drug Therapy, Combination; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects* / Q000502:physiology*; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000503:physiopathology*; D011465:Prostaglandins, Synthetic / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D011465:Prostaglandins, Synthetic; D015232:Dinoprostone